Coiled Therapeutics (LSE:COIL) is heading towards its next guided data milestone for its lead cancer drug, AO-252. In September 2026 the clinical-stage biotech said it had finished enrolling patients in the first two dose cohorts testing a new formulation of the drug. It expects initial safety and pharmacokinetic data by the end of 2026. Its most recent announcements, dated 30 September and 1 October, covered investor presentations.

What the company does

Coiled Therapeutics (LSE:COIL) develops AO-252, which it describes as a TACC3 inhibitor, for the treatment of cancer. The drug is being studied in an open-label Phase I dose-escalation trial, registered as NCT06136884. In 2026 the company developed a new lipid-based softgel formulation of AO-252. On 7 July it announced that it was advancing the next-generation formulation, and on 3 August it dosed the first patient with it.

Latest developments

On 21 September 2026 the company said two initial cohorts of the softgel formulation had completed enrolment. One cohort received 120mg twice daily and the other 160mg once daily, with three patients in each. All six patients were progressing through the assessment period set by the protocol. The company said it expects to dose up to 30 patients with the new formulation by the end of 2026. It also plans Phase I/II dose-expansion cohorts in ovarian and prostate cancer in the second half of 2026.

Earlier data with the previous tablet formulation showed an 80% clinical benefit rate with twice-daily dosing in five patients, compared with 40% with once-daily dosing in five patients. According to the interim results, no serious adverse effects were reported and the maximum tolerated dose had not been reached.

Other corporate news included the appointment of a joint corporate broker on 1 September, a director/PDMR shareholding notice on 28 September and participation in investor events in late September and early October. In June the company appointed an independent non-executive director and held its AGM.

Financial picture

The interim results to 30 June 2026, published on 28 September, showed a net loss of £3.85m for the six months and cash of about £5.10m at the end of June. The company raised £8.5m gross through a placing and subscriptions. It is pre-revenue and pays no dividend.

Sector and index context

Small UK-listed biotechs have faced a demanding funding environment, and share prices often move sharply on clinical readouts. Coiled's strategy, as described in its interim results, focuses on producing safety, pharmacokinetic and efficacy data for the new formulation to support future planning and partnering discussions. It is one of a number of clinical-stage drug developers in the FTSE AIM All Share Index.

Key risks

Early-stage oncology trials involve small patient numbers, and results may not be repeated in larger studies. The earlier efficacy figures came from very small groups and an older formulation. The company will likely need further funding to complete development, which could dilute shareholders. Timelines for trials and data can slip.

What to watch next

The key near-term milestone is the initial safety and pharmacokinetic data for the softgel formulation, which the company has guided for the end of 2026. Investors will also watch for progress towards dosing up to 30 patients, the start of the ovarian and prostate cancer expansion cohorts, and any partnering news.